Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer

Introduction The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improves recurrence-free (RFS) and overall survival (OS) in patients with FIGO stage III ovarian cancer. We evaluated the effect HIPEC on patient's health-related quality life (HRQoL) OVHIPEC trial. Materials methods was a multicentre, open-label, randomized phase trial for Patients were randomly assigned (1:1) receive CRS or without cisplatin. HRQoL assessed using EORTC QLQ-C30, (QLQ-OV28) colorectal cancer (QLQ-CR38) modules. questionnaires administered at baseline, after surgery, end treatment, every three months thereafter. secondary endpoint, prespecified focus QLQ-C30 summary score symptom scores fatigue, neuropathy gastro-intestinal symptoms. analysed linear non-linear mixed models. Results In total, 245 randomized. One-hundred-ninety-seven (80%) completed least one questionnaire. No significant difference over time observed between study arms (p-values growth: p > 0.133). pattern symptoms did not significantly differ treatment arms. Conclusion does negatively impact who are treated due extent disease. These results, together improvement RFS OS, support viability as an important option this patient population. ClinicalTrials.gov number NCT00426257. EudraCT 2006-003466-34.